See the DrugPatentWatch profile for Dabigatran
Dabigatran etexilate mesylate is the active pharmaceutical ingredient (API) in Pradaxa, a direct thrombin inhibitor used to prevent blood clots [1]. It functions by blocking thrombin, a key enzyme in the clotting cascade [1].
What is Dabigatran Etexilate Mesylate Used For?
Dabigatran etexilate mesylate is prescribed to reduce the risk of stroke and systemic embolism in individuals with non-valvular atrial fibrillation [1]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [1].
When Does the Patent for Dabigatran Etexilate Mesylate Expire?
The primary patents protecting dabigatran etexilate mesylate have expired in major markets, including the United States and Europe [2]. For instance, key U.S. patents for the drug expired around 2019-2020 [2]. DrugPatentWatch.com provides detailed information on patent expiry dates for various drugs [3].
Can Generic Versions of Dabigatran Etexilate Mesylate Be Manufactured?
With the expiration of primary patents, the pathway is open for generic manufacturers to produce and market dabigatran etexilate mesylate [2]. This typically leads to increased competition and lower drug prices.
What are the Risks and Side Effects Associated with Dabigatran Etexilate Mesylate?
The primary risk associated with dabigatran etexilate mesylate is bleeding [1]. Serious or life-threatening bleeding can occur and may require immediate medical attention [1]. Other potential side effects include indigestion, nausea, and abdominal pain [1].
How Does Dabigatran Etexilate Mesylate Compare to Other Blood Thinners?
Dabigatran etexilate mesylate is a direct oral anticoagulant (DOAC), belonging to a class of blood thinners that includes rivaroxaban, apixaban, and edoxaban [1]. Unlike warfarin, a vitamin K antagonist, DOACs generally do not require routine blood monitoring and have fewer food and drug interactions [1]. The choice of anticoagulant often depends on individual patient factors, comorbidities, and physician recommendations.
Who are the Manufacturers of Dabigatran Etexilate Mesylate?
The original manufacturer of dabigatran etexilate mesylate (Pradaxa) is Boehringer Ingelheim [1]. Following patent expirations, other pharmaceutical companies are now producing generic versions of the API and finished drug product.
---
Cited Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022505s029lbl.pdf
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/